The interesting thing about Mani Subramanian's career is how often the scale changes while the assignment stays the same. At Celera Genomics, he worked near one of biology's largest new data sets, helping annotate human and mouse genomes. At Human Genome Sciences, the unit of attention narrowed to engineered proteins and antibodies. At Gilead Sciences, it became the long choreography of clinical development. Then, after nine years inside a large pharmaceutical company, the frame changed again. He became a founder. The recurring task was translation: take a complicated piece of biology and make it legible enough for the next serious decision.
Subramanian is a physician-scientist twice over. He earned his medical degree at Armed Forces Medical College in India and a PhD in immunology and microbiology at the University of Michigan. Residency in internal medicine at University Hospitals of Cleveland and an infectious-diseases fellowship at the National Institute of Allergy and Infectious Diseases added the practical discipline of clinical training. It is an education in switching lenses: the cell, the patient, the study, the institution. Later, as an executive, he would have to add one more lens - the portfolio, where every worthy experiment competes with another worthy experiment for time.
A map before a medicine
His biotechnology career began in 2000 at Celera, during the charged period when sequencing a genome felt like producing a new atlas of life. An atlas, however, is useful only when someone labels the roads. Subramanian contributed to annotation work tied to the human, mouse and Anopheles sequencing efforts. The work is an apt prologue. Genome annotation is interpretation at industrial scale: deciding what a stretch of sequence might do, where one feature ends and another begins, and which signals deserve pursuit. It rewards accuracy, pattern recognition and a tolerance for partial answers.
In 2002 he moved to Human Genome Sciences, where the map gave way to molecules. Over eight years he worked on programs involving albumin-fusion proteins and monoclonal antibodies. The materials were different from genomic sequence, but the central problem was familiar: which biological possibility could survive contact with development? A promising mechanism has to travel through manufacturing, dosing, trial design, regulation and interpretation. Every station can expose a weakness that was invisible at the previous one.
“Our programs address the root causes of metabolic dysregulation.”Mani Subramanian, at OrsoBio's public launch in 2022
Learning the large machine
Subramanian joined Gilead in 2011 and rose to Senior Vice President and Therapeutic Area Head for Liver Diseases. His official biography credits him with oversight connected to the approvals of Sovaldi, Harvoni, Epclusa, Vosevi and Vemlidy. A list of brand names can make development sound like a trophy shelf. The underlying work is more procedural and more human: teams aligning on evidence, regulators interrogating claims, scientists revising assumptions, and leaders deciding when an apparent complication is solvable or fatal. FDA records place Subramanian in sponsor meetings during the sofosbuvir review, one seat among specialists responsible for making the case precise.
This is where a long corporate chapter can become founder training without anyone calling it that. Large organizations show what a mature development system can do. They also reveal its seams. A therapeutic-area leader sees the difference between a result that is statistically tidy and one that changes the program; between a crowded slide and a coherent thesis; between moving quickly and merely generating motion. Subramanian's Gilead years included building an R&D vision across liver diseases, not shepherding a single asset. That distinction matters because his eventual startup would arrive as a portfolio, not a lone-molecule company.
The founder as editor
In 2020 Subramanian left Gilead, joined Samsara BioCapital as a venture partner and began leading the enterprise initially called The Liver Company. By November 2022 it had become OrsoBio and stepped into public view with four clinical and preclinical programs. The launch was less a single invention than an act of assembly. Programs or intellectual property came from Gilead Sciences, Yale University, Shionogi, Phenex Pharmaceuticals and Mitobridge, an Astellas company. Scientific advisers included Gerald Shulman, Johan Auwerx and Takanori Takebe. Rob Myers, another former Gilead liver-development leader, joined as chief medical officer.
The arrangement makes Subramanian look less like the romantic inventor in a garage and more like an editor with a severe word count. Each program arrived with its own history, advocates and open questions. The founder's work was to decide why they belonged together. OrsoBio's answer was cellular energetics - the systems that govern how cells take in, store and use fuel. That idea gave a varied collection a common grammar. It also imposed a useful test: each program needed to earn its place by illuminating or changing that energy system in a way the company could measure.
Four settings, one recurring craft: turn biological complexity into the next answerable question.
There is a useful business lesson in this assembly. Coherence does not require that every idea be born in the same room. It requires a shared standard for what the ideas must prove. Companies often mistake a theme for a strategy; a collection of fashionable nouns is still just a collection. OrsoBio's early architecture was more demanding. Different mechanisms were expected to address central pathways of energy metabolism, and the team had to advance several programs in parallel without allowing breadth to become blur.
Capital buys questions
That work requires money because clinical evidence is expensive. OrsoBio announced a $60 million Series A in 2023. In September 2024 it closed an oversubscribed $67 million Series B, co-led by Ascenta Capital and Woodline Partners, with participation from existing investors that included Samsara BioCapital, Longitude Capital, Enavate Sciences, NuevaBio and Eli Lilly and Company. Subramanian described the round in practical terms: resources to advance a portfolio and build the scientific and clinical foundations for combination regimens. Capital, in this telling, is not applause. It is permission to ask a more consequential question.
Subramanian leaves Gilead, joins Samsara BioCapital and begins the venture that becomes OrsoBio.
OrsoBio launches publicly with four development programs and a cellular-energetics thesis.
The company announces a $60 million Series A financing.
An oversubscribed $67 million Series B funds further portfolio development.
Clinical results, a peer-reviewed publication and plans for the next phase move the thesis deeper into measurement.
By late 2025 the company had reported a clinical readout for TLC-6740 in combination with an established therapy and said it planned a larger Phase 2b program in 2026. A Nature Medicine paper published work on TLC-2716, a separate program, connecting preclinical development with a first-in-human study. These milestones do not settle the company's future. They do something more modest and more valuable: they replace a portion of the unknown with measured evidence. In biotech, optimism earns the meeting. Data earns the next meeting.
“This financing will enable us to build the scientific and clinical foundations.”Subramanian on OrsoBio's 2024 Series B
The second act stays unfinished
Subramanian's public persona is restrained. There is no sprawling personal media operation, no founder mythology polished into a side business. The available record is mostly professional: papers, regulatory documents, company announcements and a LinkedIn profile. That sparseness fits the arc. His story is told through institutions and teams, from a genome-sequencing company to a biologics pioneer, a major drug developer, a venture firm and now a startup. The connections are the biography.
What can another builder steal from it? First, range becomes useful only when a unifying question gives it shape. Second, experience is not a shield against uncertainty; it is a method for ordering uncertainty. Third, a portfolio is an argument. Every project should strengthen the central claim or make way for one that does. Subramanian spent decades watching ideas cross boundaries between disciplines and organizations. At OrsoBio, his job is to make those crossings happen on purpose.
A founder's second act is tempting to narrate as liberation: the seasoned executive finally escapes the large machine and follows a personal vision. The truer story is less cinematic. He carries the machine's lessons with him - the discipline of review, the patience of trials, the memory of what approval actually demands. Then he tries to preserve those virtues without importing every layer of the institution. OrsoBio is still testing that balance. It is small enough for a thesis to feel personal and mature enough for the evidence to answer back.
The career began with a map and arrived at a power bill. Genomes described the territory; therapeutic development asked what could be changed; cellular energetics asks how the system spends its resources. There is a pleasing continuity in that progression, though none of it was inevitable. Subramanian's aspiration, stated through the company, is to restore balance in systems that have lost it. His leadership challenge is the corporate version of the same idea: spend attention carefully, keep the portfolio coherent, and make every new answer earn the next question.